Humana (NYSE:HUM) Downgraded to Hold Rating by Zacks Research

Zacks Research downgraded shares of Humana (NYSE:HUM) from a strong-buy rating to a hold rating in a report published on Tuesday morning,Zacks.com reports. Zacks Research also issued estimates for Humana’s Q1 2027 earnings at $9.04 EPS.

Several other research analysts have also recently weighed in on the stock. Morgan Stanley raised shares of Humana from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $249.00 to $370.00 in a research report on Tuesday, August 4th. TD Cowen raised their price objective on shares of Humana from $350.00 to $370.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on shares of Humana in a research note on Thursday, July 30th. They set a “hold” rating on the stock. HSBC cut shares of Humana to a “hold” rating in a research note on Thursday, July 30th. Finally, Bank of America upgraded shares of Humana from a “neutral” rating to a “buy” rating and set a $500.00 price target for the company in a report on Wednesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Humana has an average rating of “Hold” and an average target price of $395.22.

Humana Stock Performance

Shares of Humana stock opened at $388.86 on Tuesday. Humana has a one year low of $163.11 and a one year high of $428.88. The company has a market cap of $46.69 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.13 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. The business’s 50 day moving average price is $380.56 and its 200 day moving average price is $274.05.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same quarter in the previous year, the company posted $6.27 earnings per share. The firm’s revenue for the quarter was up 26.2% compared to the same quarter last year. On average, research analysts predict that Humana will post 9.09 EPS for the current year.

Institutional Trading of Humana

Hedge funds have recently added to or reduced their stakes in the company. Wilkerson Advisory Group LLC grew its holdings in shares of Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock worth $66,000 after purchasing an additional 33 shares during the last quarter. Bogart Wealth LLC raised its holdings in Humana by 192.0% in the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock valued at $29,000 after buying an additional 48 shares during the last quarter. Fiduciary Alliance LLC boosted its position in Humana by 0.9% during the 1st quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider’s stock worth $976,000 after buying an additional 49 shares during the period. Sanctuary Advisors LLC boosted its position in Humana by 1.6% during the 4th quarter. Sanctuary Advisors LLC now owns 3,389 shares of the insurance provider’s stock worth $868,000 after buying an additional 52 shares during the period. Finally, Horizon Investments LLC grew its holdings in Humana by 2.5% during the 4th quarter. Horizon Investments LLC now owns 2,236 shares of the insurance provider’s stock worth $573,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.